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dementia (weighted sample= 16,272) took any antipsychotic medications; 69.7% 
were female and 68.8% were white. The average age was 85 years.  Their physical 
functions were measured by the number activities of daily living (avg. 2.92) and 
number of instrumental activity of daily living (avg. 3.6).  The most frequent diag-
noses were Alzheimer’s disease (78.8%) and vascular dementia (23.2%).  I used the 
Neuropsychiatry Inventory (NPI) for behavior problems (delusions, hallucinations, 
agitation/aggression, depression, apathy, elation, anxiety, disinhibition, irritability/
lability, and aberrant motor behavior).  I evaluated severity of dementia using the 
Clinical Dementia Rating Scale (CDR). I found that older persons with dementia 
are significantly more likely to relocate to the nursing home in 2 years if they were 
severely demented (OR= 1.3, p< .05), or were on antipsychotic medications (OR = 1.0 
p< .05), or were getting older (OR= 0.01, p< .05).  But, those who were living with 
caregiver (OR= -1.8, p< .01), or were Hispanic (OR= -1.4 p< .01) were significantly 
less likely to move to nursing homes.  Alzheimer patients were significantly more 
likely to relocate to nursing home compared to vascular dementia patients (OR= 
-1.4, p< .05). ConClusions: Community-dwelling older persons with dementia are 
more likely to move to nursing home within 2 years if they had to be medicated for 
their behavior problems and were on antipsychotic medications and, the dementia 
is more advanced
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objeCtives: In China, memantine is only reimbursed for severe dementia, while 
approved for moderately severe to severe dementia. The present model assesses 
the clinical and economic outcomes of extending national recommendations for 
memantine to moderate dementia. Methods: A Markov model was developed to 
simulate transition between health states associated with dementia. Three alter-
native strategies - no treatment, memantine prescribed from moderate to severe, 
and memantine prescribed in severe only- were compared over a five-year time 
horizon for a cohort of 1,000 patients with moderate dementia. The proportions of 
severe, dependent or aggressive patients, and caregivers’time, were estimated as 
clinical outcomes. Total costs were estimated and compared as economic outcomes. 
Deterministic sensitivity analyses were conducted to test the robustness of model 
assumptions and parameters estimates. Data inputs were taken from multiple 
sources, including clinical trials and a Delphi panel. The model adopted societal 
perspective with only direct costs considered. Results: After five years, the cohort 
of patients administered memantine from the moderate stage had developed the 
lowest proportions of severe (45%), dependent (52%) and aggressive (7%) patients, 
and necessitated less caregiver’s time (6.7hours/day). In the cohort of patients 
administered memantine in the severe stage only, these estimates were higher 
(54%, 61%, 8% and 8.35 hours/day, respectively). There were higher in patients not 
treated (64%, 77%, 13% and 9.26hours/day). Starting from the third year, memantine 
started in moderate stage incurred the lowest costs. By year five, total costs were 
RMB 182.5, 197.0 and 200.0 million for memantine from moderate, memantine in 
severe only and no treatment respectively. The sensitivity analysis produced com-
parable results. ConClusions: Over five years, memantine consistently demon-
strated higher clinical benefit when administered in moderate to severe patients as 
compared to restricted to severe and showed increasing cost-savings after 2years 
mainly due to the avoided hospitalisations.
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objeCtives: Intravenous Indomethacin and Ibuprofen are treatment of choice for 
pharmacologic closure of patent ductus arteriosus (PDA) in preterm infants accord-
ing to inhibitory effect on cyclooxygenase. However, unavailability of the intrave-
nous formulations in many countries leads to off-label use of oral NSAIDs for PDA 
closure. This study therefore aimed to determine the effectiveness and safety of oral 
NSAIDs compared to their intravenous formulations for PDA closure in preterm and/
or low birth weight infants. Methods: Randomized or quasi-randomized (RCTs) 
and observational studies comparing oral NSAIDs to intravenous Indomethacin or 
Ibuprofen with reported result of closure rate were identified. Fixed and random 
effect models were used for meta-analyses. Heterogeneity test including I2 were 
performed to assess the appropriateness of pooling the data. Results: Fourteen 
studies comparing the effectiveness and safety of oral NSAIDs (Indomethacin, 
Ibuprofen and Sulindac) with intravenous NSAIDs (Indomethacin and Ibuprofen) 
were recruited. For the primary outcome (closure rate), no statistically significant 
difference between oral Ibuprofen and intravenous NSAIDs group [five RCTs of oral 
Ibuprofen versus Intravenous Ibuprofen group; RR = 1.12 (95% CI 0.990, 1.240, I2 
23.1%)] and [four RCTs of oral Ibuprofen versus Intravenous Indomethacin group; 
RR = 1.035 (95% CI 0.755, 1.418, I2 12.7%)]. Results from the observational stud-
ies were also similar to those of RCTs. Two observational studies comparing oral 
Indomethacin and intravenous Indomethacin revealed no statistically significant 
difference (RR = 0.927 [95% CI 0.704, 1.22, I2 0.0%]). There was no significant dif-
ference in adverse outcome between oral and intravenous NSAIDs treatment 
saturation point was reached at 13 in Khyber Pakhtunkhwa province of Pakistan 
from December to February 2014. The interviews were conducted at the hospital 
pharmacy, arrangements for the time and place of interview were made during ini-
tial contacts. Written consent was obtained from the participants prior to the inter-
view. Results: Among the respondents interviewed, nine were male and four female 
hospital pharmacist aged between 25 and 50 years. Thematic content analysis yielded 5 
major themes: (a) Patients reporting (b) Lack of patient counseling (c) Lack of participa-
tion in health awareness programs, (d) Pharmacists reducing the prescribing errors, (e) 
Insufficient number of pharmacists. ConClusions: Findings revealed that hospital 
pharmacist in Pakistan are not actively participating in provision of pharmaceutical 
care services. They are facing significant hurdles for their actively participation in 
patient care, major obstacles is  the unavailability of sufficient number of pharmacist, 
lack of appropriate time for patient counseling and poor relationship between pharma-
cists and other health care providers. Moreover there is a need to explore the concept 
of pharmaceutical care among the other health care providers and general public.
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objeCtives: Paliperidone palmitate long-acting injectable (PP-LAI) is a new once-
monthly atypical antipsychotic for the treatment of schizophrenia. This article 
is to evaluate the efficacy and safety of PP-LAI in the treatment of schizophre-
nia. Methods: Published clinical studies concerning PP-LAI for schizophrenia 
were searched systemically and assessed by Jadad items. RevMan 5.2 software was 
used for data analysis and for calculating the combined outcomes of clinical tri-
als and their 95% Confidence Intervals (CI). Furthermore, sensitive analysis and 
publication bias test were conducted to assess the stability of results from Meta-
analysis. Results: 12 clinical randomized controlled trials including 39 analytic 
sets were selected for Meta-analysis. According to Jadad items, the qualities of 
including researches were high in which the rules of random grouping and balanc-
ing baseline characteristics between groups were conducted rigorously. The inci-
dence of effective cases in PP-LAI group was 1.7 (95%CI: 1.50-1.91) times higher than 
that in placebo group (Z= 8.55, P< 0.01) and equaled to the rate in risperidone group 
(RR= 1, 95%CI: 0.88-1.13). Compared with the control group of placebo (RR= 1.01, 
95%CI: 0.97-1.05) and risperidone (RR= 1.07, 95%CI: 0.98-1.16), PP-LAI seemed to 
be well tolerated, with the same incidence of adverse events. The stability of the 
present Meta-analysis was accepted without any statistical significance found by 
sensitive analysis and publication bias test. ConClusions: Paliperidone palmitate 
has certain efficacy and safety in the treatment of schizophrenia.
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objeCtives: Dementia is an irreversible brain disease that results in progressive 
cognitive impairment and, eventually, inability to carry out the simplest tasks of 
daily living. Currently there exists no cure for this disease. Patients suffering demen-
tia require plenty of care, mainly provided by the families. The objective of this 
study was to assess the time required from the patients’ caregivers according to the 
patient’s health state, and the consequences for the active population in current 
China. Methods: The current Chinese demographic structure was put in balance 
with the need of caregiving time needed by the dementia population. Demographic 
data, proportion of diagnosed and/or treated patients were provided the China 
Alzheimer’s project Memory360. A Markov model was developed to estimate the 
average caregiver’s time needed per patient per day over 5 years, separately for 
treated and not treated patients. Results: Current demographic situation in China 
is rather favourable with 70% of the population aged between 15 and 59 years (com-
pared to 60% in Europe or United States and 65% in Japan). There are approximately 
6 active persons for one elderly. It was demonstrated that over five years, untreated 
patient with dementia requires around 9.3 hours per day compared to 6.7 hours per 
day for a treated patient. It was estimated that there were 10 million patients with 
dementia in China, with only 21.3% among them receiving treatment. More than 
87 million hours per day are needed to take care of Chinese patients with dementia 
for around 910 million working people. ConClusions: In the current situation 
of China, it is estimated that in average one worker over ten will spend one hour 
per day providing care to a patient affected by dementia. Taking into account the 
rapidly aging population, this burden is likely to increase considerably in the future.
MH3
faCtors assoCiatEd witH rEloCating to nursing HoMEs aMong 
CoMMunity-dwElling oldEr PErsons witH dEMEntia
Rhee Y
Dongduk Women’s University, Seoul, South Korea
objeCtives: This study examined factors of relocating to nursing homes among 
community-dwelling older persons with dementia. Methods: This retrospective 
study used data from The Aging, Demographics, and Memory Study (ADAMS) to 
assess dementia severity and service use from 2002 to 2004 in the United States. This 
study examined psychotropic medication use among 279 older people diagnosed 
with dementia and used logistic regressions to identify factors associated with 
nursing home relocation among older persons with dementia. Results: Among 
older persons with dementia (weighted sample = 177,843), 9.2 % of persons with 
